brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - daganatellenes szerek - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
albendazol pharma vim 200 mg tabletta
ltd future pharma kft. - albendazole -
entecavir pharos 0,5 mg filmtabletta
pharos pharmaceutical oriented services ltd. - entekavirt -
entecavir pharos 1 mg filmtabletta
pharos pharmaceutical oriented services ltd. - entekavirt -
nadcad 0,5 mg filmtabletta
pharos pharmaceutical oriented services ltd. - entekavirt -
nadcad 1 mg filmtabletta
pharos pharmaceutical oriented services ltd. - entekavirt -
tacluv 0,5 mg filmtabletta
pharos pharmaceutical oriented services ltd. - entekavirt -
tacluv 1 mg filmtabletta
pharos pharmaceutical oriented services ltd. - entekavirt -
circadin
rad neurim pharmaceuticals eec sarl - melatonin - alvási beavatkozás és karbantartás - pszicholeptikumok - a circadin monoterápiaként említi az elsődleges álmatlanság rövid távú kezelését, melyet az alvás rossz minősége jellemez az 55 éves vagy annál idősebb betegek esetében.
filsuvez
amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - készítmények sebek és fekélyek kezelésére - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.